FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W156686319> ?p ?o ?g. }

• W156686319 endingPage "249" @default.
• W156686319 startingPage "245" @default.
• W156686319 abstract "Severe, intractable, chronic pain is a significant management problem for those involved in the long-term care of spinal cord injury (SCI) patients . Gabapentin, an anticonvulsant, is widely used for treating chronic pain. Ketamine, an NMDA receptor antagonist, has been available in clinical practice for 35 years. Its usefulness in pathological pain states is known. Despite this, no formal research on its effectiveness in treating neuropathic SCI pain exists.This double-blind study sought to determine the safety and efficacy of adding a multi-day low dose ketamine infusion to oral gabapentin for treating chronic pain related to post spinal cord injury.Randomized, controlled, double blind trial.Hospital, in-patient setting.Forty patients diagnosed with neuropathic pain secondary to spinal cord injury were randomized into 2 equal groups. Group I received an 80 mg intravenous ketamine infusion diluted in 500 cc normal saline over a 5 hour period daily for one week and 300 mg of gabapentin 3 times daily. Group II received a placebo infusion and 300 mg of gabapentin 3 times daily (continued) after 300 mg of gabapentin 3 times daily. Using the visual analogue scale, pain was assessed prior to treatment, daily following ketamine or placebo infusions for 7 days, and then weekly for one month after infusion termination. Side effects, specifically those related to ketamine or gabapentin, were reported.Both groups demonstrated significantly reduced pain scores compared with pre-treatment values (P < 0.05). Group I showed significant pain score improvements over Group II at all measurements (P < 0.0001) during infusion and 2 weeks after infusion termination. There was no statistical difference between the groups at 3 weeks and 4 weeks after infusion termination (P = 0.54 and P = 0.25 respectively). Both drugs were tolerated by all patients; no side effects required intervention.Multi-day low dose ketamine infusion as adjuvant to gabapentin in post-spinal cord injury related chronic pain is safe and efficacious in reducing pain, but the effect compared to placebo ceased 2 weeks after infusion termination.Study size limited to 40 patients." @default.
• W156686319 created "2016-06-24" @default.
• W156686319 creator A5089180117 @default.
• W156686319 date "2010-05-14" @default.
• W156686319 modified "2023-10-17" @default.
• W156686319 title "Multi-Day Low Dose Ketamine Infusion as Adjuvant to Oral Gabapentin in Spinal Cord Injury Related Chronic Pain: A Prospective, Randomized, Double Blind Trial" @default.
• W156686319 cites W103156734 @default.
• W156686319 cites W1547958427 @default.
• W156686319 cites W1575571855 @default.
• W156686319 cites W1603614064 @default.
• W156686319 cites W1963585627 @default.
• W156686319 cites W1972956052 @default.
• W156686319 cites W1976087780 @default.
• W156686319 cites W1979859079 @default.
• W156686319 cites W1981579423 @default.
• W156686319 cites W1986237413 @default.
• W156686319 cites W1997941230 @default.
• W156686319 cites W1998200637 @default.
• W156686319 cites W2003661021 @default.
• W156686319 cites W2017510739 @default.
• W156686319 cites W2027478301 @default.
• W156686319 cites W2029781296 @default.
• W156686319 cites W2032836087 @default.
• W156686319 cites W2038174618 @default.
• W156686319 cites W2045232188 @default.
• W156686319 cites W2048497026 @default.
• W156686319 cites W2058365209 @default.
• W156686319 cites W2118233081 @default.
• W156686319 cites W2123010774 @default.
• W156686319 cites W2144911177 @default.
• W156686319 cites W2147812749 @default.
• W156686319 cites W2156104538 @default.
• W156686319 cites W2314441349 @default.
• W156686319 cites W81776302 @default.
• W156686319 doi "https://doi.org/10.36076/ppj.2010/13/245" @default.
• W156686319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20495588" @default.
• W156686319 hasPublicationYear "2010" @default.
• W156686319 type Work @default.
• W156686319 sameAs 156686319 @default.
• W156686319 citedByCount "101" @default.
• W156686319 countsByYear W1566863192012 @default.
• W156686319 countsByYear W1566863192013 @default.
• W156686319 countsByYear W1566863192014 @default.
• W156686319 countsByYear W1566863192015 @default.
• W156686319 countsByYear W1566863192016 @default.
• W156686319 countsByYear W1566863192017 @default.
• W156686319 countsByYear W1566863192018 @default.
• W156686319 countsByYear W1566863192019 @default.
• W156686319 countsByYear W1566863192020 @default.
• W156686319 countsByYear W1566863192021 @default.
• W156686319 countsByYear W1566863192022 @default.
• W156686319 countsByYear W1566863192023 @default.
• W156686319 crossrefType "journal-article" @default.
• W156686319 hasAuthorship W156686319A5089180117 @default.
• W156686319 hasBestOaLocation W1566863191 @default.
• W156686319 hasConcept C118552586 @default.
• W156686319 hasConcept C141071460 @default.
• W156686319 hasConcept C142724271 @default.
• W156686319 hasConcept C168563851 @default.
• W156686319 hasConcept C1862650 @default.
• W156686319 hasConcept C204787440 @default.
• W156686319 hasConcept C27081682 @default.
• W156686319 hasConcept C2775858608 @default.
• W156686319 hasConcept C2776608144 @default.
• W156686319 hasConcept C2777107010 @default.
• W156686319 hasConcept C2778186239 @default.
• W156686319 hasConcept C2778334475 @default.
• W156686319 hasConcept C2780775167 @default.
• W156686319 hasConcept C2780795376 @default.
• W156686319 hasConcept C2781118164 @default.
• W156686319 hasConcept C42219234 @default.
• W156686319 hasConcept C71924100 @default.
• W156686319 hasConceptScore W156686319C118552586 @default.
• W156686319 hasConceptScore W156686319C141071460 @default.
• W156686319 hasConceptScore W156686319C142724271 @default.
• W156686319 hasConceptScore W156686319C168563851 @default.
• W156686319 hasConceptScore W156686319C1862650 @default.
• W156686319 hasConceptScore W156686319C204787440 @default.
• W156686319 hasConceptScore W156686319C27081682 @default.
• W156686319 hasConceptScore W156686319C2775858608 @default.
• W156686319 hasConceptScore W156686319C2776608144 @default.
• W156686319 hasConceptScore W156686319C2777107010 @default.
• W156686319 hasConceptScore W156686319C2778186239 @default.
• W156686319 hasConceptScore W156686319C2778334475 @default.
• W156686319 hasConceptScore W156686319C2780775167 @default.
• W156686319 hasConceptScore W156686319C2780795376 @default.
• W156686319 hasConceptScore W156686319C2781118164 @default.
• W156686319 hasConceptScore W156686319C42219234 @default.
• W156686319 hasConceptScore W156686319C71924100 @default.
• W156686319 hasIssue "3;5" @default.
• W156686319 hasLocation W1566863191 @default.
• W156686319 hasLocation W1566863192 @default.
• W156686319 hasOpenAccess W156686319 @default.
• W156686319 hasPrimaryLocation W1566863191 @default.
• W156686319 hasRelatedWork W165996248 @default.
• W156686319 hasRelatedWork W1683949753 @default.
• W156686319 hasRelatedWork W2010703163 @default.
• W156686319 hasRelatedWork W2082885661 @default.

• next